Início › Carcinoma de Células Escamosas de Cabeça e Pescoço › Pensilvânia › Pittsburgh
Ensaios clínicos de Carcinoma de Células Escamosas de Cabeça e Pescoço em Pittsburgh, PA
22 estudos para Carcinoma de Células Escamosas de Cabeça e Pescoço estão buscando participantes em locais em Pittsburgh e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
RecrutandoFase 3
- Allegheny General Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- e mais 7
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RecrutandoFase 2/3
- Site #0103, Pittsburgh
- Site #0123, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecrutandoFase 1
- Exelixis Clinical Site #32, Pittsburgh
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RecrutandoFase 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- e mais 4
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RecrutandoFase 1
- Research Site, Pittsburgh
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecrutandoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RecrutandoFase 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecrutandoFase 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- e mais 9
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
RecrutandoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RecrutandoFase 1/2
- Research Site, Pittsburgh
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RecrutandoFase 2/3
- UPMC-Magee Womens Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RecrutandoFase 2
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- e mais 5
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RecrutandoFase 2
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RecrutandoFase 1
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
RecrutandoFase 3
- GSK Investigational Site, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
RecrutandoFase 2
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RecrutandoFase 3
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
RecrutandoFase 1
- UPMC- Hillman Cancer Center, Pittsburgh
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
RecrutandoFase 2
- UPMC, Pittsburgh
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RecrutandoFase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RecrutandoFase 1
- UPMC Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
RecrutandoFase 1/2
- University of Pittsburgh, Pittsburgh
Ensaios de Carcinoma de Células Escamosas de Cabeça e Pescoço em outras cidades
- Houston, TX47 estudos
- Los Angeles, CA42 estudos
- Boston, MA40 estudos
- New York City, NY39 estudos
- Nashville, TN39 estudos
- St. Louis, MO28 estudos
- Arlington, VA26 estudos
- Philadelphia, PA26 estudos
- Chicago, IL26 estudos
- Atlanta, GA24 estudos
- San Antonio, TX22 estudos
- New Haven, CT22 estudos
Outros estudos em Pittsburgh
- Câncer de Pulmão de Não Pequenas Células48 estudos
- Câncer (todos os tipos)41 estudos
- Câncer de Mama39 estudos
- Câncer Colorretal32 estudos
- Câncer Metastático31 estudos
- Melanoma31 estudos
- Câncer de Ovário30 estudos
- Câncer Endometrial23 estudos
- Câncer de Próstata23 estudos
- Câncer de Pulmão23 estudos
- Acidente Vascular Cerebral22 estudos
- Depressão22 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.